Unresectable Extrahepatic Bile Duct Cancer Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0028791 (Unresectable Extrahepatic Bile Duct Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00238212S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaTreatment